Showing results (141-150 of 167) with videos related to

Sort By:
Pageof 17
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 16, 2017
Transition of care from pre-dialysis prelude to renal replacement therapy: the blueprints of emerging research in advanced chronic kidney diseaseKamyar Kalantar-Zadeh, Csaba P Kovesdy, Elani Streja, et al.
The Journal of Pathology|December 15, 2006
Differential response to H. pylori eradication therapy of co-existing diffuse large B-cell lymphoma and MALT lymphoma of stomach-significance of tumour cell clonality and BCL10 expressionS-H Kuo, L-T Chen, M-S Wu, et al.
Blood Cancer Journal|October 11, 2014
Genetic polymorphisms and tissue expression of interleukin-22 associated with risk and therapeutic response of gastric mucosa-associated lymphoid tissue lymphomaF Liao, Y-C Hsu, S-H Kuo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2013
A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinomaA C Roy, S R Park, D Cunningham, et al.
Oncogene|March 15, 2011
Identification of salt-inducible kinase 3 as a novel tumor antigen associated with tumorigenesis of ovarian cancerS Charoenfuprasert, Y-Y Yang, Y-C Lee, et al.
British Journal of Cancer|September 3, 2010
A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patientsT-S Yang, S-N Lu, Y Chao, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 20, 2018
Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4)N Boku, M-H Ryu, K Kato, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 10, 2020
JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusionsT Yoshino, G Pentheroudakis, S Mishima, et al.
Oncogene|August 22, 2017
miR-520h is crucial for DAPK2 regulation and breast cancer progressionC-M Su, M-Y Wang, C-C Hong, et al.
Oncogene|May 19, 2015
miR-520h is crucial for DAPK2 regulation and breast cancer progressionC-M Su, M-Y Wang, C-C Hong, et al.
Pageof 17